Christopher Benecchi - Feb 13, 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Business Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Christopher Benecchi
Stock symbol
SAGE
Transactions as of
Feb 13, 2023
Transactions value $
$0
Form type
4
Date filed
2/15/2023, 03:46 PM
Previous filing
Feb 7, 2023
Next filing
Feb 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +20.9K $0.00 20.9K Feb 13, 2023 Common Stock 20.9K $45.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,225 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 15,675 shares vesting in 36 equal monthly installments thereafter.